The key change is a much larger equity-financing tool. Tango replaces its prior $100.0M ATM program with a new prospectus supplement permitting up to $400.0M of stock sales, rather than merely extending the existing program (Other Events). The practical increase in unused capacity is approximately $364.4M, because $35.6M of the old program was still available and rolls into the new one (Other Events).
| Financing detail | Filing figure |
|---|---|
| Prior ATM authorization | $100.0M (Other Events) |
| Shares sold under prior ATM | $64.4M (Other Events) |
| Unsold prior capacity carried forward | $35.6M (Other Events) |
| New total ATM capacity | $400.0M (Other Events) |
| Approximate incremental capacity | $364.4M (calculated from Other Events) |
This is not an immediate capital raise. The company has authorized the ability to sell up to $400.0M of stock through the market, but the filing does not disclose a new sale, proceeds received, pricing, or a timetable for issuance. The near-term financial impact is therefore prospective rather than an immediate cash infusion.
Versus the prior standing expectation, the financing overhang is materially larger. Investors already knew Tango had an ATM program and roughly $35.6M of remaining capacity; the surprise is the expansion to $400.0M. That improves access to cash but also creates substantially more potential dilution than the previously disclosed program, making the net read mildly negative absent evidence that the capital is urgently needed or will fund value-creating milestones.
The filing changes financing flexibility, not the operating outlook. It contains no new clinical data, partnership terms, guidance, cash-runway update, or financial results. The main information is the expanded ability to issue equity, with actual dilution dependent on whether and when Tango uses the ATM (Other Events).
Read the original 8-K on SEC EDGAR ↗